Abstract: An increasing number of applications use nanospecie-fluorescent labeling technology; however, no established guidelines are available to warrant their safety for potential clinical use. Here, rTg4510 transgenic mice and their littermate controls were injected with fluorogold, a nanospecie tracer, or phosphate buffered saline (PBS) targeted to the right amygdala. No significant abnormal behavior was detected in any mice injected with PBS. After fluorogold injection, however, rTg4510 mice displayed persistent left-sided neurological deficits and left circling behavior for up to 14 days post-injection, while control mice demonstrated a transient syndrome. Mortality occurred only in rTg4510 mice and statistically significant differences appeared independent of age. An immunofluorescent study revealed TUNEL positive cells that were heavily and extensively distributed in the periamygdalar region that overlapped with the fluorogold deposit region in rTg4510 mice, whereas control mice showed only sporadic distribution of TUNEL-positive cells. Colocalization of TUNEL and caspase-3 active peptide immunoreactivity was identified in a subset of the cells, indicating an involvement of caspase-dependent apoptotic mechanisms. In conclusion, fluorogold induces damage in the central nervous system most noticeably in mice over-expressing human mutant tau.
INTRODUCTION
Fluorogold (hydroxystilbamidine) is well accepted as a fluorophore due to its luminescing characteristics. Its molecular formula of C 16 H 16 N 4 O (molecular mass: 280.324) categorizes it into the nanospecie superfamily for manufacturing nanostructures (World Intellectual Property Organization: WO/2005/102396). There are increasing applications deriving from these nanospecie-fluorescent labeling technologies. For example, gene expression profiling and drug discovery are two major fields currently utilizing this technology. Noticeably, magnetic resonance (MR)-coupled fluorescence tomography is emerging as a method for imaging molecular targets in living animals (Davis et al., 2008) . Furthermore, fluorophores--such as cross-linked iron oxides--may be born on nanoparticles thereby providing compounds visible by both fluorescence microscopy and MRI (Jaffer et al., 2007) . These advances in science and technology predict a boom in the manufacture of fluorophore-containing nanospecie(s). Because the technology has the potential for clinical diagnostic and therapeutic purposes, there is a safety concern about whether the introduced nanospecie fluorophore(s) might cause adverse biological outcomes in situ. Currently, there are no established guidelines in regulating such applications.
Since its introduction in 1986 (Schmued and Fallon 1986) as a retrograde tracer for labeling neuronal connections and axonal transport, hundreds of studies have *Address correspondence to this author at the Division of Neurotoxicology, HFT-132, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas 72079-9502, USA; taken advantage of the properties of fluorogold which include high resistance to fading, no uptake by intact undamaged fibers of passage, a long half-life and compatibility with other neurohistochemical techniques. The commercial availability of fluorogold-antibodies further predicts expanding fluorogold applications. Recent reports favor fluorogold as a safe compound for in vivo interventions. In larval lamprey, fluorogold appeared not to cause neuronal death (McClellan et al., 2006) . No toxic effects were detected in retrogradely labeled neurons in the parasympathetic preganglion or in the anterior horn of S1 spinal cord segments in adult rats following intraperitoneal injections of fluorogold (Akhavan et al., 2006) . Fluorogold has been injected into the cochlea of rats and Java monkeys to label the eighth cranial nerve. Its entrance into the brainstem and the primary radiation of auditory fibers into the cochlear nucleus allow the acquisition of living images under appropriate ultraviolet illumination, demonstrating its potential for clinical diagnostic applications (Marangos et al., 2001) . Intra-parenchymal injections of fluorogold into the hippocampus, mediodorsal thalamic nucleus, dorsal raphe nucleus, and amygdala have been performed in rats (Vereczki et al., 2006; McDonald and Mascagni, 2007; Lee et al., 2007; Poulin et al., 2006) with no indication of harmful effects.
A concern over fluorogold toxicity was recently raised during preliminary experiments in our lab in which mortality was observed following injections of 2 μl of 2% fluorogold into the amygdala of rTg4510 mice, a mouse model overexpressing human mutant P301L tau and developing tauopathy with significant neuronal loss (Santacruz et al., 2005) . Here, fluorogold was used in order to examine whether or not over-expression of the human mutant tau would interfere with axonal transport (Zehr et al., 2007) . While mechanisms underlying the neuronal death in tauopathies remain unclear, there is increasing evidence indicating that cell death in Drosophila over-expressing wild-type and mutant R406W tau occurs independent of neurofibrillary tangle (NFT) development (Wittmann et al., 2001) , in mice expressing wild-type human tau (Andorf er et al., 2005) , and in rTg4510 mice that express human mutant tau (Spires et al., 2006) . The observation that fluorogold killed rTg4510 mice after injection into the amygdala suggested that over-expression of human mutant tau might sensitize animals to fluorogold, thus, linking development of tauopathy to enhanced cell death. Alternatively, rTg4510 mice might otherwise be more sensitive to fluorogold toxicity via some other mechanism.
Suspecting fluorogold toxicity, the protocol for amygdalar injection was changed so that the amount administered was reduced by half. Interestingly, following a parenchymal injection of 2 μl of 1% fluorogold, 4-month-old or older rTg4510 mice consistently showed abnormal behavior, persistent left turning and paralytic neurological deficits, but most survived. After generating scales to semiquantitatively score circling behavior and neurological deficits, 2.5 month old double transgenic mice (rTg4510), single transgenic mice [either the mutant tau (T-mouse) or the tetracycline-dependent transcription activator (tTa) (Ca2+-calmodulin kinase II promoter) transgenic (Cmouse)], and non-transgenic (NT mice) were monitored after fluorogold injection. Since 4 genotypes of mice were produced by crossing mice with the responder mutant tau P301L transgene with mice expressing the tTa activator transgene (as described previously by Santacruz et al., 2005) , the F1 littermates with all 4 genotypes were used in order to determine whether or not single transgene mice (i.e. T-mice or C-mice) show significant toxic responses to fluorogold. To identify fluorogold-induced brain parenchymal damage, a triple staining method, successfully used previously to define ischemic neuronal death (He et al., 2006) , was employed to co-localize TdT-mediated X-dUTP nick end labeling (TUNEL) with caspase-3 activated peptide (C3AP) immunoreactivity and nuclei stained with 4',6-diamidino-2-phenylindole (DAPI). Furthermore, natural fluorogold fluorescent images, fluorogold-labeled cells and intraparenchymal fluorogold deposits, were acquired to correlate the damaged region with fluorogold labeling or injection.
MATERIALS AND METHODS

Animals
rTg4510 mice and their littermate controls (total n=122) at 2.5-, 4-and 5.5-months of age were used. The institutional IACUC approved the experimental protocol. Animals were individually housed. F1 littermates generated from crossmating animals carrying either the mutant tau 301L transgene or the tTa transgene were subjected to an intraparenchymal fluorogold injection. For most animals, the survival time post surgery was monitored for 14 days (n=91). A subgroup of animals (n=31) aged 2.5 months old was sacrificed 3 days post surgery to correlate behavioral changes with immunohistochemical evaluation of cellular damage using the aforementioned triple staining method.
Surgery
After induction of anesthesia with Avertin® (intraperitoneal injection at 250 mg/kg), each animal's head was fixed in a stereotaxic frame. The needle of a 10 μl syringe (World Precision Instruments, Inc. Sarasota, FL) was stereotactically inserted to a depth 3.7 (2.5 month old) or 4.2 mm (4-months-old or older) from the brain surface into the right amygdala through a burr-hole placed 2.0 mm posterior to Bregma and 2.6 mm lateral to the midline. It took 10 minutes to inject 2 μl of 1% fluorogold or PBS, which was controlled by an ultramicroPump connected to Micro 4™ microsyringe pump controller (World Precision Instruments, Inc. Sarasota, FL). As surgical controls, 10 mice aged 2.5 months old received 2 μl of PBS injections: 5 rTg4510 mice, 3 non-transgenic mice, and 2 single transgenic mice (1 Tmouse and 1 C-mouse). Neurological deficits were evaluated as previously described with modifications (He et al., 1999 (He et al., , 2000 (He et al., , 2004 , while criteria for assessing the circling behavior were established following a preliminary experiment with adult ( 4mo old) mice.
Zhen He
Evaluation of Behavioral Changes
Animals aged 2.5-months were systematically evaluated using 2 scales, a neurological deficit scale and a circling behavior scale as shown in Table 1 . Digital photos and videos were acquired to document typical behavioral changes. Each animal's behavior was assessed at 1, 3, 6, and 24 hours, and 3 or 14 days following surgery. The neurological deficit scale was established by consulting previous reports (He et al., 1999 (He et al., , 2000 (He et al., , 2004 . In general, walking/moving speed and static and moving postures were the major parameters that were scored. Stimuli such as gentle pushes were sometimes applied to assist confirmation of the assessment. Scoring behaviors according to the grading system in Table 1 , ambulatory and postural changes were tabulated. The criteria used for assessing the circling behavior were established following a preliminary experiment in adult (> 4mo old) mice. Circling speed was measured as rotations per minute (rpm). Animals not showing circling behaviors or any paralytic signs were scored "0" (normal). Animals persistently walking along its home cage perimeter and turning in a leftward direction were scored "1". Animals displaying circling behavior were scored "2" when circling speed was lower than 30 rpm and "3" when higher than 30 rpm. Animals were scored as "4" when they turned over along the longitudinal axis of their body. The highest score of "5" was given when animals developed complete hemispheric paralysis.
Tissue Preparation
Animals were killed by cervical dislocation followed by decapitation. The brains were immediately dissected and immersion-fixed in buffered formalin for 48 hours. The whole brains of 14-day survival animals were cut into 30 μm-thick coronal slices using a microtome and preserved in PBS-sodium azide solution. The brains of 3-day survival animals were processed for paraffin embedding in tissue blocks containing the dorsal hippocampus and amygdala. These tissue blocks were cut into 5 μm-thick coronal slices.
Natural Fluorogold Fluorescent Images
The 30 μm-thick brain slices were serially mounted on glass slides and dried overnight at 37°C. After two washes with distilled water, the slices were sealed in Fluoromount-G (SouthernBiotech, Birmingham, AL). The fluorescent images were acquired on an Eclipse 80i microscope (Nikon Corporation, Tokyo, Japan) outfitted with a "Fluorogold" filter (410 nm excitation filter/450 nm pass filter cube) and Metamorph software (Molecular Devices, Downingtown, PA, U.S.A.).
Triple Staining with TUNEL, C3AP and DAPI
Paraffin-embedded, 5 μm-thick slices were used for the fluorescent study as previously described (He et al., 2006) . Briefly, direct TUNEL labeling was performed using "In Situ Cell Death Detection Kit, Fluorescein" (Roche Applied Science, Penzberg, Germany) following the manufacturer's protocol. After the washing and blocking procedures, sections were incubated with rabbit-anti-C3AP (1:200, R&D Systems, Minneapolis, MN) overnight at 4°C as reported previously (He et al., 2002 (He et al., & 2005 . The secondary antibody used was a goat anti-rabbit (1: 200, Alexa 594-labeled) antibody (Molecular Probes, Eugene, OR). The DNA in nuclei was visualized using DAPI. Images for TUNEL, C3AP immunoreactivity, or DAPI staining were acquired using different camera channels with appropriate filters (FITC, Texas red and DAPI, respectively) with the aforementioned microscope.
Statistics
Wilcoxon's rank sum test was used for statistic treatment of behavioral scores in 2.5 month-old mice (n=36) subjected to fluorogold injection. Mean neurological deficit and circling behavior scores for individual animals were generated by averaging 3~24 hour behavior scores. A Chisquare test was used for mortality within 14 days following surgery (n=91). P<0.05 was considered significant.
RESULTS
Mortality
As demonstrated in Table 2 , 81 mice that were given an intraparenchymal injection of 2 μl of 1% fluorogold survived for 14 days, while 10 rTg4510 mice died following the fluorogold injection. Mortality was only observed in the rTg4510 group. There were no significant differences in 14-day survival among the rTg4510 subgroups of different ages: 2.5-month vs. 4.0-month or 5.5-month groups. Eight out of 10 deaths occurred following recovery from anesthesia, between 24 hours and 96 hours post surgery. No deaths occurred in the 3-day survival subgroup (2.5-month-old animals and n=31).
Behavior Changes
Systematic evaluations of neurological deficits and circling behaviors were performed for all of the 2.5-monthold animals: 15 animals in the 14-day survival and 31 animals in the 3-day survival protocols. In the latter cohort, 5 rTg4510 mice, 3 nontransgenic mice and 2 single transgenic mice received 2 μl of PBS injections. No appreciable neurological deficits were detectable in any mice (rTg4510 or their littermate controls) injected with PBS. Nontransgenic mice had a neurological deficit score of 1 at 1 hour following the fluorogold injection and the signs gradually dissipated. However, after flourogold injections, the mean neurological scores (exclusively left sided), were above 2 or 3 in rTg4510 mice. Similarly, there was no occurrence of circling behavior in mice after PBS injections. Non-transgenic mice transiently showed the left circling behavior and then recovered to normal following fluorogold injections. rTg4510 mice scored an average of above 3 in Fig. (1) . Mean neurological deficit and circling behavior scores from 3 to 24 hours after surgery in fluorogold-treated mice. No appreciable neurological deficits or circling behaviors were detected in any animals: rTg4510 (n=5), single transgenic (n=2) or nontransgenic mice (n=3), injected with PBS. No significant differences were identified between single transgenic mice (tau-only mice: n=8 and tTa-only mice: n=5) and nontransgenic mice (n=12) in either neurological deficit or circling behavior scores. rTg4510 mice (n=11) displayed significantly higher scores than non-transgenic littermates in both neurological deficits and circling behaviors (p<0.001). P score = paralytic neurological deficit score; C score = circling score. leftward circling behavior during the first hour following fluorogold injection and maintained this abnormal behavior at a detectable level for 14 days. Using the Wilcoxon rank sum test, mean neurological deficit and circling behavior scores after the fluorogold injections are summarized in Fig.  (1) . rTg4510 mice displayed significantly higher scores than non-transgenic littermates in both neurological deficits and circling behaviors (p<0.001). No significant differences in either neurological deficits or circling behaviors were detected between single transgenic mice (tau-only and tTaonly mice) and non-transgenic mice.
Fluorogold Labeling Study
As shown in the schematic illustration (left upper panel of Fig. 2) , fluorogold was injected targeting the right amygdala. There were 2 major sources of fluorogold fluorescent signals 14 days following the injection: the periamygdalar region and the parietal cortex. Fluorogold appeared in the peri-amygdalar region as a residual component after stereotaxic injection (left lower panel of Fig. 2) and pyramidal neurons located in the parietal cortex layers III-V (right upper panel of Fig. 2) were labeled with flourogold via axonal transport from the injection location.
Fluorescent Study of Fluorogold-Induced Damage
Needle-path-associated damage was identified in rTg4510 mice injected with vehicle (right lower panel of Fig.  3 ) or fluorogold (inset of Fig. 3) . Interestingly, there was no similar damage in any of 3 non-transgenic mice injected with vehicle (right upper panel of Fig. 3) . Far more extensive than needle-path-associated damage, TUNEL positive cells were sporadically distributed in non-transgenic mice injected with fluorogold (left upper panel of Fig. 3) . Noticeably, TUNEL positive cells were heavily and extensively distributed in the peri-amygdalar region of the rTg4510 mice (left lower panel of Fig. 3) . Co-localization of TUNEL and caspase-3 active peptide immunoreactivity was observed in a subset of the cells. In the amygdalar region (Fig. 4) , TUNEL-positive cells and caspase-3 active peptide immunoreactivity were verified in rTg4510 mice injected with fluorogold. Again, colocalization of TUNEL and caspase-3 active peptide immunoreactivity was identified in a subset of the cells. As   Fig. (2) . Fluorogold injection site and fluorogold-labeling/deposit. Fluorogold-labeled neurons are distributed in the parietal cortex, layers III-V, 14 days following injection into the amygdala, while fluorogold deposits occur predominantly in the peri-amygdalar region. The insets display the cortex and the peri-amygdalar regions using a hematoxylin and eosin staining method.
indicated by arrowheads, a few clustered nuclei were apoptotic, displaying macrophage-like morphology.
In general, fluorogold-induced damage, identified by the triple staining method, was distributed in the peri-amygdalar region parallel to the fluorogold deposit region as shown in Fig. (2) . Few TUNEL/C3AP-positive cells, other than those associated with the needle-path-damage, were observed in layers III-V of the parietal cortex, where most of neurons would be labeled by fluorogold.
DISCUSSION
There are 3 novel findings in the present study. First, fluorogold injections result in persistent neurological deficits and circling behaviosr in mice that over-express human mutant tau, but not in controls. Second, fluorogold injections cause mortality in rTg4510 mice, but not in controls. Finally, heavily labeled TUNEL-positive cells are observed at the injection site (peri-amygdalar) following fluorogold injections in rTg4510 mice. Less-heavily labeled TUNELpositive cells are seen in non-transgenic mice. Because the distribution of TUNEL-stained cells appears to overlap the fluorogold deposit region far more extensively than in the areas damaged by vehicle-injection surgery, fluorogold is primarily responsible for the toxic effects.
Fluorogold as a nanospecie tracer may have potential in clinical diagnostic and therapeutic applications, providing living fluorescent images. Currently, there is increasing use of MR imaging-contrast nanoparticles in the preclinical field. Intravenous injections of nanoemulsions of perfluorocarbons are being employed to monitor inflammatory responses in vivo following cardiac and cerebral ischemia using fluorine magnetic resonance imaging (Flögel et al., 2008) . MR imaging is capable of detecting super-paramagnetic iron oxide nanoparticle conjugated antibodies in vivo, facilitating cancer-diagnosis and therapy (Neumaier et al., 2008) . Nanospecies themselves may serve as anticancer agents (Zhang et al., 2008) . Nevertheless, the concept of an ideal nanoparticle platform has been proposed that would exhibit no toxicity to blood cellular components and "invisibility" to immune cells (Dobrovolskaia et al., 2008) . Activation of macrophages, however, has been reported as one of the adverse responses seen in mice that are administered carbon nanotubes (Chou et al., 2007) . The present study demonstrates clustered apoptotic cells (Fig. 4) exhibiting a macrophage-like morphology. Thus, fluorogold may cause similar damage as one of the nanospecie superfamily members. It is worthy of mentioning that the toxicity of fluorogold is significantly enhanced in the central nervous system of mice with neuronal tauopathy as demonstrated in the present study. Since nanostructures/nanoparticles may be utilized in the treatment of diseases/disorders, their ability to affect pathophysiological status may be essential in determining their value for diagnostic or therapeutic use. Their safety needs to be assessed under in both pathophysiological and normal conditions. Mechanisms underlying fluorogold toxicity remain unclear. Nevertheless, a subset of TUNEL-positive cells was co-localized with caspase-3 active peptide immunoreactivity ( Fig. 3 and 4) , suggesting an involvement of caspasedependent apoptotic mechanisms. Using a triple staining method, no substantial damage was detected 3 days after flourogold injection in the parietal cortex where neurons in layers III-V were clearly labeled by fluorogold via axonal transport ( Fig. 2 and Zehr et al., 2007) . Also, in our preliminary experiment using the triple staining method, similar results were found in one-day survival animals: TUNEL/C3AP-positive cells were detected in the periamygdalar region or in the cortex limited to the peripheral region of the needle-path. Accordingly, abnormal axonal transport might not account for the occurrence of the observed apoptosis. Alternately, an acute, concentrationdependent, cell-body-direct toxicity of fluorogold is plausible for explaining the damage.
Vulnerability of rTg4510 mice to fluorogold toxicity warrants further investigation. It is known that rTg4510 mice age-dependently develop neurofibrillary tangles (NFTs), neuronal loss, and memory loss (Santacruz et al., 2005) . Little tau pathology exists at 1 month; however, pre-tangles can be observed in the hippocampus and cortex of these mice by 2.5 months, with argyrophilic tangles developing by 4-5.5 months. Tau expression in this model relies on the expression of tTA protein driven by the CamKIIalpha promoter. tTA binds the tetracycline operator sequences within the minimal CMV promoter and drives the expression of the tau transgene containing an frontotemporal dementia with Parkinsonism linked to chromosome 17 mutation, P301L. Presence of both transgenes results in 15X tau overexpression in the forebrain (hippocampus and cortex) that can be repressed with doxycycline. Importantly, the cognitive dysfunction in older rTg4510 mice was reversed by repressing tau expression, despite the pre-existence of brain atrophy and neuronal loss and the continued accumulation of the 64kD insoluble tau species and NFTs (Santacruz et al., 2005) . The present study has verified the occurrence of cell death in the peri-amygdalar region, where fluorogold heavily deposits and TUNEL-positive and C3AP-TUNEL-positive cells are extensively distributed in 2.5 month old rTg4510 mice. Of interest is whether or not formation of pre-tangles plays a role in the vulnerability to flourogold toxicity. In future studies, a quantitative determination of apoptotic and necrotic cell numbers may provide clues for elucidating the mechanisms underlying fluorogold toxicity. In addition, administration of doxycycline to inhibit expression of the human mutant tau may clarify its role in the vulnerability of rTg4510 mice to flourogold.
Circling behavior (either left or right) may occur spontaneously in a very small percent of intact transgenic mice and underlying mechanisms are not known. However, the time course and reproducibility of the circling behavior (exclusively leftward) following fluorogold injection strongly suggests a toxic effect in the right amygdala. Often, initial clinical responses to a traumatic event are driven by the amygdala, often in the form of the "fight-or-flight" response (Vieweg et al., 2006) and circling behavior might be a type of "flight/escape" response. Since the hippocampus and prefrontal cortex are proposed to be involved in anxietylike behaviors, fluorogold transmitted to these regions via axonal transport may continuously stimulate behaviors Fig. (4) . Amygdalar damage induced by fluorogold injection. Apoptotic cell death was verified by the observation of condensed, deformed nuclei delineated by positive DAPI and TUNEL-staining, which was co-localized with C3AP-immunoreactivity that demonstrates activation of caspase-3. associated with such states and, thus, contribute their persistence. Damage to other brain structures may also play a role in the mechanism of the left-circling behavior, because these animals also demonstrate persistent hemispheric paralysis on their left sides.
CONCLUSION
Fluorogold (2μl, 1%), a nanospecie tracer, can be neurotoxic. Over-expression of human mutant tau may result in an increased vulnerability to such toxicity. While nanospecie labeling technology has potential clinical diagnostic and therapeutic applications for the central nervous system, toxicity-screening measures should be taken for such probes, particularly in conditions of existing pathophysiology.
